Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Treatment of Chemotherapy-Induced Anemia Using Epoetin Alfa Biosimilar for Patients with Lymphoma and Myeloma: The Synergy Study

Florian Scotté, Kamel Laribi, Christian Gisselbrecht, Dominique Spaeth, Emna Kasdaghli, MD, Hélène Albrand, MD, Eric Leutenegger, Isabelle Ray-Coquard

Blood (2015) 126 (23): 952.

https://doi.org/10.1182/blood.V126.23.952.952

Published: 2015

Journal Articles

Epoetin Alfa Biosimilar Treatment for Chemotherapy-Induced Anemia in Current Oncology and Hematology Practice: An Iron Supplementation Subanalysis of the Synergy Study

Florian Scotté, Kamel Laribi, Christian Gisselbrecht, Dominique Spaeth, Emna Kasdaghli, MD, Hélène Albrand, MD, Eric Leutenegger, Isabelle Ray-Coquard

Blood (2015) 126 (23): 3363.

https://doi.org/10.1182/blood.V126.23.3363.3363

Published: 2015

Journal Articles

Good Usage of Biosimilar Filgrastim: A Subanalysis of the Next Study

Stephane Leprêtre, Frédéric Maloisel, Didier Kamioner, Christian Berthou, Hélène Albrand

Blood (2014) 124 (21): 4974.

https://doi.org/10.1182/blood.V124.21.4974.4974

Published: 2014

Journal Articles

Safety of Biosimilar Filgrastim in Patients Undergoing Neutropenia-Inducing Chemotherapy: The Next Study

Stephane Leprêtre, Frédéric Maloisel, Didier Kamioner, Christian Berthou, Hélène Albrand

Blood (2014) 124 (21): 4976.

https://doi.org/10.1182/blood.V124.21.4976.4976

Published: 2014

Journal Articles

Safety of Biosimilar Filgrastim in Patients with Haematological Malignancies Undergoing Neutropenia-Inducing Chemotherapy: A Subanalysis of the Next Study

Stephane Leprêtre, Frédéric Maloisel, Didier Kamioner, Christian Berthou, Hélène Albrand

Blood (2014) 124 (21): 4977.

https://doi.org/10.1182/blood.V124.21.4977.4977

Published: 2014

Journal Articles

Recommended Usage of Epoetin Alpha Biosimilar Retacrit™: A Subanalysis of the Orheo Study

Mauricette Michallet, MD PhD, Pierre Soubeyran, MDPhD, Elisabeth Luporsi, Jean-Emmanuel Kurtz, Hélène Albrand

Blood (2014) 124 (21): 1330.

https://doi.org/10.1182/blood.V124.21.1330.1330

Published: 2014

NARROW

Treatment of Chemotherapy-Induced Anemia Using Epoetin Alfa Biosimilar for Patients with Lymphoma and Myeloma: The Synergy Study

Epoetin Alfa Biosimilar Treatment for Chemotherapy-Induced Anemia in Current Oncology and Hematology Practice: An Iron Supplementation Subanalysis of the Synergy Study

Good Usage of Biosimilar Filgrastim: A Subanalysis of the Next Study

Safety of Biosimilar Filgrastim in Patients Undergoing Neutropenia-Inducing Chemotherapy: The Next Study

Safety of Biosimilar Filgrastim in Patients with Haematological Malignancies Undergoing Neutropenia-Inducing Chemotherapy: A Subanalysis of the Next Study

Recommended Usage of Epoetin Alpha Biosimilar Retacrit™: A Subanalysis of the Orheo Study

Email alerts

ASH Publications

American Society of Hematology

Treatment of Chemotherapy-Induced Anemia Using Epoetin Alfa Biosimilar for Patients with Lymphoma and Myeloma: The Synergy Study

Epoetin Alfa Biosimilar Treatment for Chemotherapy-Induced Anemia in Current Oncology and Hematology Practice: An Iron Supplementation Subanalysis of the Synergy Study

Good Usage of Biosimilar Filgrastim: A Subanalysis of the Next Study

Safety of Biosimilar Filgrastim in Patients Undergoing Neutropenia-Inducing Chemotherapy: The Next Study

Safety of Biosimilar Filgrastim in Patients with Haematological Malignancies Undergoing Neutropenia-Inducing Chemotherapy: A Subanalysis of the Next Study

Recommended Usage of Epoetin Alpha Biosimilar Retacrit™: A Subanalysis of the Orheo Study

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only